Biogen (BIIB) EBT Margin Growth (3y) (2012 - 2026)
Powered by 
Analysis
Biogen (BIIB) EBT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 443.00 |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -15,548.00 |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | -484.00 |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 132.00 |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 6,691.00 |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -2,054.00 |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 9,980.00 |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -2,399.00 |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -1.89 Mn |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 31,363.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,399.00 |
| Mar 31, 2026 | -255.00 |
| Dec 31, 2025 | -2,619.00 |
| Sep 30, 2025 | -3,267.00 |
| Jun 30, 2025 | -2,091.00 |
| Mar 31, 2025 | -92.00 |
| Dec 31, 2024 | -294.00 |
| Sep 30, 2024 | 781.00 |
| Jun 30, 2024 | 737.00 |
| Mar 31, 2024 | 296.00 |
| Dec 31, 2023 | -15.00 |
| Sep 30, 2023 | -3,395.00 |
| Jun 30, 2023 | -2,651.00 |
| Mar 31, 2023 | -3,029.00 |
| Dec 31, 2022 | -2,334.00 |
| Sep 30, 2022 | 524.00 |
| Jun 30, 2022 | 41.00 |
| Mar 31, 2022 | -3,958.00 |
| Dec 31, 2021 | -2,530.00 |
| Sep 30, 2021 | -4,223.00 |